NCT06397781Not yet recruitingPhase 4
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 30 Apr 2024
- Start date
- 1 Jan 2031
- Primary completion date
- Dec 2035
- Lead sponsor
- Boston Children's Hospital
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06397781
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 100
- From 1 Jan 2031 to the primary completion date, Dec 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, azathioprine, methotrexate)
- Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
- Use of topical steroids, topical calcineurin inhibitors within 7 days
- Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
Other illness
- Hypersensitivity to an agent used for the skin decolonization protocol
- History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
- Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
- Febrile illness at time of visits
- Suspected immune deficiency or family history of primary immunodeficiency
Other
- . Enrollment in another clinical trial
- Phototherapy for AD within 4 weeks
- Bleach baths within 7 days of the first Visit
- Use of oral or topical antibiotics within 21 days of the beginning of the study
- Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
- Pregnancy
Who the study is looking for
- Male or female participants ≥6 yrs of age
- Meet atopic dermatitis Standard Diagnostic Criteria
- SCORAD \> 40.
Age in the registry: 6 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boston Children's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.